MRO Tracker · Pharma
Monthly and half year pharmaceutical exports, by product group and region. Updated when official monthly trade data is released.
USD 16.14 bnexports in H1 FY27, +4.9%
USD 2.74 bnSeptember 2026, +4.68%
73.84%share of formulations and biologicals
+12.07%growth in bulk drugs and intermediates
MRO View: Growth has slowed from 9.4% in FY25 to under 5% this half, as shipments to the US moderated. The fastest gains came from ASEAN, Latin America and Europe, and bulk drugs grew more than three times as fast as formulations.
Headline numbers
| Period | Exports | Growth |
|---|---|---|
| H1 FY27 (Apr to Sep 2026) | USD 16,135.93 mn | 4.9% |
| H1 FY26 (Apr to Sep 2025) | USD 15,382.85 mn | |
| Q2 FY27 (Jul to Sep 2026) | USD 8.04 bn | 3.05% |
| September 2026 | USD 2,744.05 mn | 4.68% |
| FY25 full year | USD 30.47 bn | 9.4% |
By product group, H1 FY27
| Group | Exports | Share | Growth |
|---|---|---|---|
| Drug formulations and biologicals | USD 11.91 bn | 73.84% | 3.81% |
| Bulk drugs and drug intermediates | USD 2.75 bn | 17.0% | 12.07% |
| Surgicals | USD 427 mn | 2.6% | 9.53% |
Growth by region, H1 FY27
21.54%
16.58%
9.66%
6.48%
| Region | Exports | Growth |
|---|---|---|
| ASEAN | Growth only | 21.54% |
| Latin America and Caribbean | Growth only | 16.58% |
| Europe (20.38% of total) | USD 3,288.27 mn | 9.66% |
| Africa | Growth only | 6.48% |
| North America, incl. United States | Growth only | Moderated |
Region values other than Europe are not part of the half year release; growth rates are shown so the direction of each market is clear. Shares of bulk drugs and surgicals are MRO calculations on the H1 total. The tracker is refreshed each month when new export data is released.
Need the numbers behind this tracker?
We break down export demand by molecule, country and buyer for pharma clients.
Get the monthly India tracker updateNew state data and new plant announcements in one short email, once a month.
One email a month. Reply to any email to unsubscribe. Privacy policy